Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

by Barry101 | Apr 20, 2018 | Press Release

ORLANDO, Fla., April 20, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) (“Hemispherx” or the “Company”), a research and development and emerging commercial growth company focused on unmet medical needs in immunology, with a special...

Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs

by Barry101 | Apr 17, 2018 | Press Release

ORLANDO, Fla., April 17, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, is pleased to announce that it has successfully achieved a developmental...

Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients

by Barry101 | Apr 4, 2018 | Press Release

Early Access Programs are Known as “Special Access Programme” in CanadaORLANDO, Fla., April 04, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, said it amended its agreement with Netherlands-based...

Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017

by Barry101 | Apr 2, 2018 | Press Release

ORLANDO, Fla., April 02, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on immuno-pharmaceutical research and the commercial development of its immunology products Ampligen® and Alferon®, announced its financial results for the year...